01—Abstract
Summary
Summary of the 10-Q filed August 5, 2025. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. reported a net loss of $183.8 milliona for the three months ended June 30, 2025, compared with a net loss of $75.5 million in the same period of 2024, and a net loss of $353.4 million for the six months ended June 30, 2025 (versus $111.7 million a year earlier).
Total revenues, net were $110.6 millionb for the quarter, including net product revenue of $71.5 million from Attruby in the U.S., license and services revenue of $37.4 million (which includes a $30.0 million regulatory milestone under the Eidos-Alexion License Agreement), and royalty revenue of $1.6 million from Beyonttra in the EU and Japan. Selling, general and administrative expenses rose to $129.2 million from $59.5 million, driven by commercial launch investments, while research and development expenses were $111.2 million, down from $114.7 million. The balance sheet shows cash, cash equivalents and marketable securities of $756.9 million as of June 30, 2025, against total liabilities of $2.86 billion and a total stockholders' deficit of $1.78 billion.
Financing activity during the period included the issuance of $575.0 millionc of 1.75% convertible senior notes due 2031 and the repayment of the $450.0 million term loan under the Amended Financing Agreement. On June 27, 2025, the company sold a portion of its future royalties on Bayer's EU sales of acoramidis to royalty purchasers for $300.0 million in cash. The company states that its existing resources will fund operations for at least the next 12 months from the filing date, and that it expects to continue incurring operating and net losses for at least the next several years.
During the quarter, the company's Attruby and Beyonttra commercial products were approved in the EU, Japan and UK, and the company implemented newly designed internal controls in connection with the commercial launch. Management concluded that disclosure controls and procedures were effective as of June 30, 2025.
02—Key points
Key Highlights
- Net product revenue of $71.5 million for the quarter ended June 30, 2025, from Attruby sales in the U.S., versus no product revenue in the prior-year quarter
- Total revenues, net of $110.6 million for the quarter, up from $2.2 million a year earlier, including a $30.0 million regulatory milestone under the Eidos-Alexion License Agreement
- Net loss of $183.8 million for the quarter and $353.4 million for the six months ended June 30, 2025, compared with $75.5 million and $111.7 million in the respective 2024 periods
- Selling, general and administrative expenses of $129.2 million for the quarter, up from $59.5 million, primarily reflecting commercial launch investments
- Cash, cash equivalents and marketable securities of $756.9 million as of June 30, 2025, and a total stockholders' deficit of $1.78 billion
- Issued $575.0 million of 1.75% convertible senior notes due 2031 and fully repaid the $450.0 million term loan under the Amended Financing Agreement
- Sold a portion of royalties on Bayer's EU acoramidis sales for $300.0 million in cash on June 27, 2025, recorded as long-term debt
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 5, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $110.56M$2.17M | +4999.9% |
| Cost of Revenue | $3.65M$598K | +510.9% |
| Gross Profit | $106.91M$1.57M | +6709.7% |
| R&D Expenses | $111.23M$114.69M | −3.0% |
| SG&A Expenses | $129.15M$59.52M | +117.0% |
| Operating Expenses | $244.84M$177.71M | +37.8% |
| Operating Income | -$134.28M-$175.54M | +23.5% |
| Interest Expense | $11.59M$8.58M | +35.1% |
| Net Income | -$181.90M-$73.46M | −147.6% |
| EPS (Basic) | $-0.95$-0.39 | −143.6% |
| EPS (Diluted) | $-0.95$-0.39 | −143.6% |
| Shares Outstanding (Basic) | 190.52M187.59M | +1.6% |
| Shares Outstanding (Diluted) | 190.52M187.59M | +1.6% |
05—Questions
Frequently Asked Questions
How much revenue did BridgeBio generate in the second quarter of 2025, and where did it come from?
Total revenues, net were $110.6 million for the three months ended June 30, 2025. This consisted of $71.5 million of net product revenue from Attruby in the U.S., $37.4 million of license and services revenue (including a $30.0 million regulatory milestone under the Eidos-Alexion License Agreement), and $1.6 million of royalty revenue from Beyonttra sales in the EU and Japan.
Why did operating expenses increase so much compared with last year?
Selling, general and administrative expenses increased to $129.2 million for the quarter from $59.5 million, primarily due to a $38.0 million increase in external costs and a $24.9 million increase in personnel-related expenses, which the filing attributes largely to investments supporting the commercial launch and ongoing activities of Attruby. Research and development expenses decreased slightly to $111.2 million from $114.7 million.
What is BridgeBio's liquidity position and how is it funded?
As of June 30, 2025, the company had cash, cash equivalents and marketable securities of $756.9 million. The company states these resources will fund operations for at least the next 12 months from the filing date based on current plans, but it expects to continue incurring operating and net losses for at least the next several years and may need additional funding sooner if its plans change.
What new debt and financing transactions occurred in 2025?
On February 28, 2025, the company issued $575.0 million of 1.75% convertible senior notes due 2031 with net proceeds of approximately $563.0 million, and used the proceeds to repay the $450.0 million term loan and repurchase 1,405,411 shares of common stock for $48.3 million. On June 27, 2025, it sold a portion of its future royalties on Bayer's EU sales of acoramidis for $300.0 million in cash, which the company accounts for as long-term debt.
Did the company disclose any material legal proceedings or changes to risk factors?
The filing states that BridgeBio was not party to any material legal proceedings as of the filing date. It also states that, other than risk factors disclosed in its Q1 2025 Form 10-Q, there were no material changes to the risk factors in its 2024 Form 10-K.
06—Continue